Skip to main navigation
Skip to search
Skip to main content
Pontificia Universidad Javeriana Home
Help & FAQ
Link opens in a new tab
Español
English
Search content at Pontificia Universidad Javeriana
Home
Profiles
Units
Research output
Projects
Equipment
Courses
Activities
Prizes
Press/Media
Datasets
Impacts
Student theses
Immunotherapy of systemic sclerosis
Christina G. Katsiari
, Theodora Simopoulou
,
Ioannis Alexiou
, Lazaros I. Sakkas
University of Thessaly
Research output
:
Contribution to journal
›
Review article
›
peer-review
15
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Immunotherapy of systemic sclerosis'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Systemic Sclerosis
100%
Intravenous Immunoglobulin (IVIg)
100%
Tocilizumab
75%
Mycophenolate Mofetil
75%
Cyclophosphamide
75%
Abatacept
75%
Immune Activation
50%
Methotrexate
50%
Rituximab
50%
Belimumab
50%
Microvasculopathy
50%
Fresolimumab
50%
T Cells
25%
High Mortality
25%
B Cells
25%
In Vitro Study
25%
Disease Course
25%
Fibroblasts
25%
Disease Process
25%
Cell-to-cell
25%
Therapeutic Efficacy
25%
Collagen
25%
Lung Function
25%
Hand Function
25%
Internal Organs
25%
Collagen Deposition
25%
Chronic Systemic Disease
25%
Transplant Immunosuppression
25%
Autologous Stem Cell Transplantation (auto-SCT)
25%
Medicine and Dentistry
Systemic Scleroderma
100%
Immunoglobulin
100%
Immunotherapy
100%
Cyclophosphamide
75%
Tocilizumab
75%
Mycophenolate Mofetil
75%
Abatacept
75%
Rituximab
50%
Fresolimumab
50%
Methotrexate
50%
Belimumab
50%
Biological Product
25%
Lung
25%
Disease Course
25%
B Cell
25%
T Cell
25%
In Vitro
25%
Immunosuppressive Treatment
25%
Systemic Disease
25%
Disease Process
25%
Autologous Stem Cell Transplantation
25%
Hand Function
25%
Immunosuppressant
25%
Fibroblast
25%
Immunology and Microbiology
Immunotherapy
100%
Intravenous Immunoglobulin
100%
Systemic Scleroderma
100%
Tocilizumab
75%
Abatacept
75%
Cyclophosphamide
75%
Mycophenolate Mofetil
75%
Rituximab
50%
Methotrexate
50%
Fresolimumab
50%
Belimumab
50%
B Cell
25%
Immunosuppression
25%
Lung
25%
Biological Product
25%
T Cell
25%
Hand Function
25%
Autologous Stem Cell Transplantation
25%
Immunosuppressant
25%
Fibroblast
25%
In Vitro
25%
INIS
immunotherapy
100%
immunoglobulins
100%
diseases
75%
skin
75%
cyclophosphamide
75%
methotrexate
50%
collagen
50%
modifications
25%
deposition
25%
animals
25%
lungs
25%
drugs
25%
mortality
25%
in vitro
25%
organs
25%
hands
25%
stem cells
25%
immunosuppression
25%
fibroblasts
25%